Full-Body Cardiovascular and Tumor MRI for Early Detection of Disease: Feasibility and Initial Experience in 298 Subjects

[Whole body MRI--diagnostic strategy of the future?]

Whole body magnetic resonance imaging (MRI) opens new opportunities in diagnostic radiology as systemic disease entities can be examined with high sensitivity. This can lead to a change of paradigm, so that not only organ-related but rather disease-specific MRI examination protocols can be applied which focus on the underlying pathophysiology of the disease. Whole body MRI has already been successfully used for several oncological and non-oncological indications. In addition, whole body MRI has broadened the discussion regarding its use for secondary prevention. Compared to computed tomography, MRI does not use radiation. Although whole body MRI is still in an early stage, the enormous medical and economical potential can be envisioned.

[Screening in cardiovascular diseases]

Cardiovascular disease still ranks number one in the mortality statistics in the industrialized world. In Germany the five most common causes of death are all associated with arteriosclerotic changes of the arterial vasculature. As the treatment often extends over long periods and it can be impossible for patients to work, peripheral arterial occlusive disease (PAOD) constitutes a not inconsiderable economic factor. Thus, screening for arteriosclerotic disease seems to be reasonable, because the potential for influencing arteriosclerotic changes is known to be higher in an early stage of the disease even before symptoms become apparent. Not every case can be cured, but progression can frequently be slowed down. The need for invasive procedures, some of them associated with ionizing radiation, limited the use of imaging of the arterial vasculature for a long time. Noninvasive clinical examinations such as the "ankle brachial index" (ABI) can indicate the presence of PAOD, though exact localization of the pathologic changes is not possible except with imaging methods. In contrast to these, MRI is a noninvasive imaging modality that does not involve ionizing radiation but offers high spatial resolution arterial imaging.

Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology

The advent of positron emission tomography-computed tomography (PET-CT) and whole-body magnetic resonance imaging (WB-MRI) has introduced tumor imaging with a systemic and functional approach compared with established sequential, multimodal diagnostic algorithms.Whole-body PET with [18F]-fluoro-2-desoxy-glucose is a useful imaging procedure for tumor staging and monitoring that can visualize active tumor tissue by detecting pathological glucose metabolism. The combination of PET with the detailed anatomical information of multislice computed tomography as dual-modality scanners has markedly increased lesion localization and diagnostic accuracy compared with both modalities as standalone applications.Hardware innovations, such as the introduction of multi-receiver channel whole-body MRI scanners at 1.5 and, recently, 3 T, combined with acquisition acceleration techniques, have made high-resolution WB-MRI clinically feasible. Now, a dedicated assessment of individual organs with various soft tissue contrast, spatial resolution, and contrast media dynamics can be combined with whole-body anatomical coverage in a multiplanar imaging approach. More flexible protocols (eg, T1-weighted turbo spin-echo and short inversion recovery imaging, dedicated lung imaging or dynamic contrast-enhanced studies of the abdomen) can be performed within 45 minutes.Whole-body magnetic resonance imaging has recently been proposed for tumor screening of asymptomatic individuals, and potentially life-changing diagnoses, such as formerly unknown malignancy, have been reported. However, larger patient cohort studies will have to show the cost efficiency and the clinical effectiveness of such an approach.For initial tumor staging, PET-CT has proved more accurate for the definition of T-stage and lymph node assessment, mainly because of the missing metabolic information in WB-MRI. However, new applications, such as magnetic resonance whole-body diffusion-weighted imaging or lymphotropic contrast agents, may significantly increase sensitivity in near future. Whole-body magnetic resonance imaging has shown advantages for the detection of distant metastatic disease, especially from tumors frequently spreading to the liver or brain and as a whole-body bone marrow screening application. Within this context, WB-MRI is highly accurate for the detection of skeletal metastases and staging of multiple myeloma. This article summarizes recent developments of CT/PET-CT and WB-MRI and highlights their performance within the scope of systemic oncological imaging.

Whole-body screening of atherosclerosis with magnetic resonance angiography

With whole-body magnetic resonance angiography (WBMRA), it is possible to examine the whole arterial tree except intracranial and coronary vessels in a single examination without the risks involved in ionizing radiation or arterial cannulation. Whole-body magnetic resonance angiography is well suited for repeated clinical examinations in patients with systemic diseases such as vasculitis or atherosclerosis and can also be used for scientific purposes. On the basis of the WBMRA overview, a possible further development of the WBMRA concept can be to perform further acquisitions at sites with atherosclerotic plaques with higher-resolution scans to determine the degree of stenosis more accurately or to achieve plaque characterization. A total validation of WBMRA compared with digital subtraction angiography (DSA) is not possible owing to the hazards of ionizing radiation. Studies have shown a high sensitivity and specificity for the pelvic and lower limb arteries in comparison with DSA. No systematic validation against DSA has been performed for the renal, aortic, and carotid arteries. Various methods have been used, however, for confirmation of vascular abnormalities found on WBMRA such as ultrasonography, dedicated MRA, or DSA, with reasonably high agreement. The WBMRA method has not been studied with regard to prediction of future cardiovascular (CV) events, as have intima media thickness, coronary artery calcium scoring, and the ankle-brachial index. The full usefulness of WBMRA in an epidemiological setting and as a complementary screening tool for assessing CV risk still needs to be validated against future CV events.

Lung MRI at 1.5 and 3 Tesla

OBJECTIVES

To compare the image quality and lesion contrast of lung MRI using 5 different pulse sequences at 1.5 T and 3 T.

MATERIALS AND METHODS

Lung MRI was performed at 1.5 T and 3 T using 5 pulse sequences which have been previously proposed for lung MRI: 3D volumetric interpolated breath-hold examination (VIBE), true fast imaging with steady-state precession (TrueFISP), half-Fourier single-shot turbo spin-echo (HASTE), short tau inversion recovery (STIR), T2-weighted turbo spin-echo (TSE). In addition to 4 healthy volunteers, 5 porcine lungs were examined in a dedicated chest phantom. Lung pathology (nodules and infiltrates) was simulated in the phantom by intrapulmonary and intrabronchial injections of agarose. CT was performed in the phantom for correlation. Image quality of the sequences was ranked in a side-by-side comparison by 3 blinded radiologists regarding the delineation of pulmonary and mediastinal anatomy, conspicuity of pulmonary nodules and infiltrates, and presence of artifacts. The contrast of nodules and infiltrates (CNODULES and CINFILTRATES) defined by the ratio of the signal intensities of the lesion and adjacent normal lung parenchyma was determined.

RESULTS

There were no relevant differences regarding the preference for the individual sequences between both field strengths. TSE was the preferred sequence for the visualization of the mediastinum at both field strengths. For the visualization of lung parenchyma the observers preferred TrueFISP in volunteers and TSE in the phantom studies. At both field strengths VIBE achieved the best rating for the depiction of nodules, whereas HASTE was rated best for the delineation of infiltrates. TrueFISP had the fewest artifacts in volunteers, whereas STIR showed the fewest artifacts in the phantom. For all but the TrueFISP sequence the lesion contrast increased from 1.5 T to 3 T. At both field strengths VIBE showed the highest CNODULES (6.6 and 7.1) and HASTE the highest CINFILTRATES (6.1 and 6.3).

CONCLUSION

The imaging characteristics of different pulse sequences used for lung MRI do not substantially differ between 1.5 T and 3 T. A higher lesion contrast can be expected at 3 T.

High-Resolution Whole-Body Magnetic Resonance Imaging Applications at 1.5 and 3 Tesla

OBJECTIVES

To analyze the impact of altered magnetic field properties on image quality and on potential artifacts when an established whole-body magnetic resonance imaging (WB-MRI) protocol at 1.5 Tesla (T) is migrated to 3 T.

MATERIALS AND METHODS

Fifteen volunteers underwent noncontrast magnetic resonance imaging (MRI) on 32-channel whole body-scanners at 1.5 and 3 T with the use of parallel acquisition techniques (PAT). Coronal T1-weighted TSE- and short tau inversion recovery (STIR)-sequences at 4 body levels including sagittal imaging of the whole spine were performed. Additional axial HASTE-imaging of lung and abdomen, T1-/T2-weighted-TSE- and EPI-sequences of the brain and T2-weighted respiratory-triggered imaging of the liver was acquired. Both data sets were compared by 2 independent readers in respect to artifacts and image quality using a 5-point scale. Regions of pronounced artifacts were defined.

RESULTS

Overall image impression was both qualitatively rated as "good" at 1.5 and 3 T for T1-w-TSE- and STIR-imaging of the whole body and spine. At 1.5 T, significantly better quantitative values for overall image quality were found for WB-STIR, T2-w-TSE imaging of the liver and brain (Wilcoxon Mann-Whitney U Test; P < 0.05), overall rated as good at 3 T. Significantly higher dielectric effects at 3 T were affecting T1-w- and STIR-WB-MRI, and HASTE of the abdomen and better image homogeneity at 1.5 T was observed for T1-weighted-/STIR-WB-MRI and T1-w-TSE-imaging of the spine. Pulsation artifacts were significantly increased at 3 T for T1-w WB-MRI. Significantly higher susceptibility artifacts were found for GRE-sequences of the brain at 3 T. Motion artifacts, Gibbs-Ringing, and image distortion was not significantly different and showed slightly higher quantitative values at 3 T (except for HASTE imaging of the abdomen). Overall scan time was 45 minutes and 44 seconds at 1.5 T and 40 minutes and 28 seconds at 3 T at identical image resolution.

CONCLUSION

Three Tesla WB-MRI is feasible with good image quality comparable to 1.5 T. 3.0 T WB-MRI shows significantly more artifacts with a mild to moderate impact on image assessment. Therefore 1.5 T WB-MRI is the preferred image modality. Overall scan time at 3 T is reduced with the use of parallel imaging at a constant image resolution.

In vivo mouse imaging and spectroscopy in drug discovery

Imaging modalities such as micro-computed tomography (micro-CT), micro-positron emission tomography (micro-PET), high-resolution MRI, optical imaging, and high-resolution ultrasound have become invaluable tools in preclinical pharmaceutical research. They can be used to non-invasively investigate, in vivo, rodent biology and metabolism, disease models, and pharmacokinetics and pharmacodynamics of drugs. The advantages and limitations of each approach usually determine its application, and therefore a small-rodent imaging laboratory in a pharmaceutical environment should ideally provide access to several techniques. In this paper we aim to illustrate how these techniques may be used to obtain meaningful information for the phenotyping of transgenic mice and for the analysis of compounds in murine models of disease.

The Prevalence and Quantification of Atherosclerosis in an Elderly Population Assessed by Whole-Body Magnetic Resonance Angiography

OBJECTIVE

The principal aim of the present study was to explore the feasibility of using whole-body magnetic resonance angiography to assess atherosclerosis in different vascular territories in a cohort of elderly.

METHODS AND RESULTS

Three hundred six 70-year-old subjects (145 women, 161 men) recruited from a population-based cohort study (Prospective Investigation of the Vasculature in Uppsala Seniors, ie, the PIVUS study) underwent 1.5-T whole-body magnetic resonance angiography with gadodiamide. The arteries were divided into 26 segments. In total, 7956 vessel segments were evaluated with 7900 segments (99.3%) possible to evaluate. Of these, 7186 segments (91%) were normal. Luminal narrowing of > or = 50% was observed in 9 (1.5%) of the renal arteries, 12 (1.8%) of the carotid arteries, in 31 segments (1.1%) of the pelvic/upper leg territories, and in 136 segments (6.2%) of territories in the lower leg. Approximately one-third of the sample had no vascular abnormalities, one-third had stenoses of < 50%, and the remainder had stenoses > or = 50% or occlusions. Six subjects (2%) had aortic aneurysms. In subjects without evident vascular disease, 26% had significant vascular abnormalities.

CONCLUSIONS

Whole-body magnetic resonance angiography performed with a clinical scanner can be used for quantifying atherosclerosis in different vascular territories in a single examination in an elderly population.

Whole-body MR vascular screening detects unsuspected concomitant vascular disease in coronary heart disease patients

Coronary heart disease (CHD) patients often show atherosclerotic vascular disease in other vascular territories. We evaluated how often whole-body MR imaging detects concomitant arterial pathologies in CHD patients, and how often these pathologies were not known to the patients previously. Of 4,814 participants in the population-based Heinz Nixdorf Recall Study, 327 reported CHD (i.e., previous coronary bypass surgery, angioplasty); of those, 160 patients (mean age 66.4 years) were examined using MR of the brain, the heart (excluding the coronary arteries), and whole-body MR angiography. The prevalence of each vascular pathology was assessed, correlated to the others and compared to patients' histories. Of the 160 CHD patients, 16 (10%) showed MR signs of stroke, and 77 (48.1%) had a stenosis >50% in at least one extracerebral peripheral artery (other than the coronaries), including 28 (17.5%) with relevant renal artery stenoses, and 20 (12.5%) with relevant extracerebral internal carotid artery stenoses. False negative histories were reported in 12 of 81 cases with myocardial infarctions, and in 11 of 16 cases with cerebrovascular infarctions. This whole-body atherosclerosis MR screening program allows previously unknown concomitant vascular disease to be detected in coronary heart disease patients. Its prospective value should be assessed in further studies.

Myocardial Scars More Frequent Than Expected

OBJECTIVES

The aim of this study was to investigate the prevalence of clinically recognized myocardial infarctions (RMIs) and unrecognized myocardial infarctions (UMIs) in 70-year-old subjects, assessed with magnetic resonance imaging (MRI), and to relate the findings to cardiac function and morbidity.

BACKGROUND

Late enhancement MRI identifies myocardial scars and thereby has the potential to detect UMI.

METHODS

Cardiac MRI was performed on 259 randomly chosen 70-year-old subjects. Late enhancement and cine sequences were acquired, and the ejection fraction and left ventricular (LV) mass were calculated. Late enhancement involving the subendocardial layer was considered to represent myocardial infarction (MI) scars, and their volumes were calculated. Information on cardiac morbidity and risk factors was collected from medical records and from a health examination. Subjects with MI scars, with or without a hospital diagnosis of MI were classified as RMI or UMI, respectively.

RESULTS

The images from 248 subjects (123 women, 125 men) were assessable. Myocardial infarction scars were found in 60 subjects (24.2%), in 49 of whom (19.8%) they were UMIs. The volumes of the UMIs were significantly smaller than those of the RMIs. There was an increased frequency of chest pain symptoms among the subjects with UMI or RMI compared with those without MI scars. Ejection fraction was significantly lower and LV mass significantly larger in the subjects with UMI or RMI than in those without MI scars.

CONCLUSIONS

Unrecognized MI detected with MRI was more frequent than expected in 70-year-old subjects. The subjects displaying these UMIs may represent a previously unknown potential risk group for future cardiovascular events.

Total-body MR-imaging in oncology

Although MRI is an effective modality in oncology, state-of-the-art total-body MRI (TB-MRI) in the past was infeasible in the diagnostic work-up, due to the need for repeated examinations with repositioning and separate surface coils to cover all body parts. To overcome this limitation, either a moving table platform in combination with the body-coil or a special designed rolling table platform with one body phased-array coil have been implemented with promising results for both tumor staging and metastases screening. Since 2004, state-of-the-art TB-MR imaging with high spatial resolution has become feasible using a newly developed 1.5 Tesla TB-MRI system with multiple receiver channels. This review gives an overview based on the recent literature as well as our own experience concerning the possibilities, challenges, and limitations of TB-MRI in oncology, emphasizing both oncological staging and early tumor detection in asymptomatic subjects.

Whole-body MRI and PET-CT in the management of cancer patients

Mortality rate, prognosis, and treatment outcome of cancer patients depend strongly on the detection of malignancy at an early stage and efficient monitoring of the disease. Multimodality diagnostic approaches are now widely applied for tumor detection, staging, and follow-up. However, the introduction of whole-body imaging modalities into clinical practice has substantially expanded diagnostic options. PET-CT has increased diagnostic accuracy by providing "anatometabolic" information by fusing tumor glucose-uptake measures from the PET examination and accurate delineation of anatomical structures given by spiral CT. Since PET-CT is associated with high doses of ionizing radiation, it is used in mainly tumor staging and screening within the scope of tertiary prevention. Here promising results have been reported for various tumor entities. MRI provides excellent tissue contrast, detailed morphological information and lack of ionizing radiation. MRI has been employed for the assessment of focal pathologies in specific anatomical regions. Whole-body MRI scanners using multiple receiver channels with parallel acquisition techniques now allow tumor screening from head to toe within substantially shorter examination times and without compromises in image resolution. We report our experience with these two novel techniques and discuss their benefits and drawbacks in terms of systemic tumor screening.

MR colonography in inflammatory bowel disease

Colonography based on magnetic resonance imaging (MRI) appears to be a promising technique for polyp assessment in the colon. Several studies have evaluated this method for colonic assessment in patients with inflammatory bowel disease. We briefly review different methodologies such as dark lumen and bright lumen techniques for abdominal MRI. In addition, recently published studies concerning the sensitivity and accuracy in detecting inflammatory bowel changes in inflammatory bowel disease using MRI are discussed.

Emerging techniques: Whole-body screening and staging with MRI

Strategies for screening or tumor staging include various modalities such as plain radiography, computed tomography (CT), MRI, and ultrasound. Technical innovations have created the feasibility to use MRI to image the entire body in a relatively short time-period. Whole-body MRI may play a potentially important role in evaluating for cancer or vascular disease. This article describes the rationale for using MRI to display the entire body, the techniques employed in whole-body MRI, possibilities and limitations, and summarizes first clinical results for screening and staging purposes.

Future Horizons in MR Imaging

In this article, we defined the major areas of active research in clinical MR imaging. Further increases in the number of parallel coils within an imaging array and in advances in parallel imaging pulse sequences and postprocessing will lead to further reductions in imaging time analogous to the impact of multidetector CT on helical CT. The synergism between parallel and high-field imaging will aid the development of high-field imaging. The combined dynamic and hepatic parenchymal enhancement of new contrast agents that have or may soon receive FDA approval will enable improved detection and characterization of liver lesions. The lymphotropic SPIO agents will remain an active area of clinical research to further assess their role in oncologic staging. Molecular imaging contrast research using magnetic particles and MR microscopy will continue to flourish. Screening examinations by MR imaging will re-main an area of research for the short- and intermediate term, with the final outcome dependent more on socioeconomic costs than the underlying capability of achieving high-quality screening studies.

Future directions in body magnetic resonance imaging

Technologic innovations in instrumentation and contrast agents naturally lead to new clinical and research applications in body MRI. Although long-range predictions of innovation are an uncertain process, short-term trends in development are more readily discernable. This review will provide examples of recent developments in magnetic resonance spectroscopic imaging, contrast agent development and molecular imaging, instrumentation, post-processing, and screening in an attempt to describe areas of active research.

Whole-body magnetic resonance imaging

Whole-body magnetic resonance imaging is a fast and accurate modality for the detection of disease throughout the entire body. Technical improvements including the availability of different high image quality MR sequences, the remote movement of the imaging table, and the use of specialized surface coils have rendered whole-body screening with MRI a feasible method. In this article we describe underlying techniques and report on first clinical experiences of whole-body magnetic resonance imaging as a staging and screening method. Furthermore, advantages and limitations compared with whole-body imaging based on computed tomography are discussed.